Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share. This is a 40.91 percent decrease over losses of $(0.44) per share from the same period last year.
July 7, 5:43 PM
April 29, 6:24 PM
Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million.
HC Wainwright & Co. Initiates Coverage On Syndax Pharmaceuticals with Buy Rating, Announces Price Target of $31
April 11, 7:38 AM
HC Wainwright & Co. analyst Edward White initiates coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and announces Price Target of $31.
Syndax Pharma Offers Added Data Showing ‘Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613’
December 13, 3:47 PM
- 55% overall response rate and 24% CR/CRh rate in relapsed/refractory acute leukemia patients with NPM1 or MLLr mutations; no discontinuations due to treatment-related adverse events - - CR/CRh rates of 23% and 24% in
Syndax Pharmaceuticals Announced Updated Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease at ASH 2021; Said 68% Overall Response Rate And Broad Multiorgan Clinical Benefit Observed In H…
December 11, 5:55 PM
Syndax Pharmaceuticals, Inc.